Waypoint Biomedical Holdings Stock Performance
| WYPH Stock | USD 0.0003 0.00 0.00% |
WayPoint Biomedical holds a performance score of 10 on a scale of zero to a hundred. The firm maintains a market beta of -26.39, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning WayPoint Biomedical are expected to decrease by larger amounts. On the other hand, during market turmoil, WayPoint Biomedical is expected to outperform it. Use WayPoint Biomedical Holdings market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness , to analyze future returns on WayPoint Biomedical Holdings.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in WayPoint Biomedical Holdings are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite fairly fragile basic indicators, WayPoint Biomedical demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
WayPoint |
WayPoint Biomedical Relative Risk vs. Return Landscape
If you would invest 0.01 in WayPoint Biomedical Holdings on September 26, 2025 and sell it today you would earn a total of 0.02 from holding WayPoint Biomedical Holdings or generate 200.0% return on investment over 90 days. WayPoint Biomedical Holdings is currently generating 17.5298% in daily expected returns and assumes 128.2112% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than WayPoint, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
WayPoint Biomedical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for WayPoint Biomedical's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as WayPoint Biomedical Holdings, and traders can use it to determine the average amount a WayPoint Biomedical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1367
| Best Portfolio | Best Equity | WYPH | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average WayPoint Biomedical is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of WayPoint Biomedical by adding it to a well-diversified portfolio.
WayPoint Biomedical Fundamentals Growth
WayPoint Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of WayPoint Biomedical, and WayPoint Biomedical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on WayPoint Pink Sheet performance.
| Operating Margin | (28.55) % | |||
| Current Valuation | 2.73 M | |||
| Shares Outstanding | 37.42 M | |||
| Price To Sales | 25.77 X | |||
| Revenue | 29.74 K | |||
| EBITDA | (947.03 K) | |||
| Cash And Equivalents | 2.47 K | |||
| Total Debt | 234.17 K | |||
| Book Value Per Share | (0.01) X | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 66.44 K | |||
About WayPoint Biomedical Performance
By evaluating WayPoint Biomedical's fundamental ratios, stakeholders can gain valuable insights into WayPoint Biomedical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if WayPoint Biomedical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if WayPoint Biomedical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
WayPoint Biomedical Holdings, Inc., through its wholly owned subsidiary, WayPoint Biomedical, Inc., engages in the development and marketing of diagnostic tests and devices for screening and monitoring human health, fitness, and environment. WayPoint Biomedical Holdings was founded in 2004 and is based in Huntington Beach, California. Waypoint Biomed operates under Shell Companies classification in the United States and is traded on OTC Exchange.Things to note about WayPoint Biomedical performance evaluation
Checking the ongoing alerts about WayPoint Biomedical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for WayPoint Biomedical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| WayPoint Biomedical is way too risky over 90 days horizon | |
| WayPoint Biomedical has some characteristics of a very speculative penny stock | |
| WayPoint Biomedical appears to be risky and price may revert if volatility continues | |
| WayPoint Biomedical has high likelihood to experience some financial distress in the next 2 years | |
| WayPoint Biomedical Holdings currently holds 234.17 K in liabilities. WayPoint Biomedical has a current ratio of 0.06, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist WayPoint Biomedical until it has trouble settling it off, either with new capital or with free cash flow. So, WayPoint Biomedical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like WayPoint Biomedical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for WayPoint to invest in growth at high rates of return. When we think about WayPoint Biomedical's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 29.74 K. Net Loss for the year was (544.28 K) with loss before overhead, payroll, taxes, and interest of (28.96 K). |
- Analyzing WayPoint Biomedical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether WayPoint Biomedical's stock is overvalued or undervalued compared to its peers.
- Examining WayPoint Biomedical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating WayPoint Biomedical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of WayPoint Biomedical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of WayPoint Biomedical's pink sheet. These opinions can provide insight into WayPoint Biomedical's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for WayPoint Pink Sheet analysis
When running WayPoint Biomedical's price analysis, check to measure WayPoint Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy WayPoint Biomedical is operating at the current time. Most of WayPoint Biomedical's value examination focuses on studying past and present price action to predict the probability of WayPoint Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move WayPoint Biomedical's price. Additionally, you may evaluate how the addition of WayPoint Biomedical to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |